Concussions are gaining attention as a risk factor for Alzheimer's disease (AD). Previous reports suggest concussion, also called head injury (HI), may be associated with changes to AD biomarkers, including amyloid and tau. However, there has been little characterization of biofluid biomarkers in older adults with remote history of HI.
Objective
We investigated whether aging participants at risk for AD with self-reported HI history would demonstrate alterations to cerebrospinal fluid (CSF) and blood plasma biomarkers of AD.
Methods
Using two-way ANCOVAs and linear mixed effects models, we examined both baseline cross-sectional and longitudinal associations between HI history, cognition, and AD biofluid biomarkers in 100 participants with HI history compared to 2411 without HI history from the ADNI dataset.
Results
On baseline analysis, participants with HI history had higher CSF Aβ42/40 ratios than non-HI participants. There were no other baseline differences in biomarkers between HI and non-HI participants, nor were there any main effects of HI upon longitudinal analysis. We observed consistent main effects of age and cognitive impairment that suggested a pattern of worsened AD biomarker signatures in impaired participants with increasing age.
Conclusions
Our findings do not support an association between self-reported HI history and AD fluid biomarkers in older adults from the ADNI dataset. Further characterization of fluid biomarker trajectories both in the acute post-HI period and in participants with remote HI is needed to understand the temporal dynamics of fluid biomarkers after HI and the implications of HI for AD risk.
ThalDRRübUOrantesM, et al.Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology2002; 58: 1791–1800.
4.
BraakHAlafuzoffIArzbergerT, et al.Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol2006; 112: 389–404.
5.
LiuCCLiuCCKanekiyoT, et al.Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol2013; 9: 106–118.
6.
LivingstonGHuntleyJSommerladA, et al.Dementia prevention, intervention, and care: 2020 report of the lancet commission. Lancet2020; 396: 413–446.
7.
HowellDRSouthardJ. The molecular pathophysiology of concussion. Clin Sports Med2021; 40: 39–51.
8.
GizaCCHovdaDA. The neurometabolic cascade of concussion. J Athl Train2001; 36: 228–235.
9.
UryuKLaurerHMcIntoshT, et al.Repetitive mild brain trauma accelerates Abeta deposition, lipid peroxidation, and cognitive impairment in a transgenic mouse model of Alzheimer amyloidosis. J Neurosci2002; 22: 446–454.
10.
IkonomovicMDUryuKAbrahamsonEE, et al.Alzheimer's pathology in human temporal cortex surgically excised after severe brain injury. Exp Neurol2004; 190: 192–203.
11.
ShivelySScherAIPerlDP, et al.Dementia resulting from traumatic brain injury: what is the pathology?Arch Neurol2012; 69: 1245–1251.
12.
IwataAChenXHMcIntoshTK, et al.Long-term accumulation of amyloid-beta in axons following brain trauma without persistent upregulation of amyloid precursor protein genes. J Neuropathol Exp Neurol2002; 61: 1056–1068.
13.
EdwardsG3rdZhaoJDashPK, et al.Traumatic brain injury induces tau aggregation and spreading. J Neurotrauma2020; 37: 80–92.
14.
WalkerAChapinBAbisambraJ, et al.Association between single moderate to severe traumatic brain injury and long-term tauopathy in humans and preclinical animal models: a systematic narrative review of the literature. Acta Neuropathol Commun2022; 10: 13.
15.
KatzDIBernickCDodickDW, et al.National institute of neurological disorders and stroke consensus diagnostic criteria for traumatic encephalopathy syndrome. Neurology2021; 96: 848–863.
16.
McKeeACAloscoMLHuberBR. Repetitive head impacts and chronic traumatic encephalopathy. Neurosurg Clin N Am2016; 27: 529–535.
17.
McKeeACSteinTDKiernanPT, et al.The neuropathology of chronic traumatic encephalopathy. Brain Pathol2015; 25: 350–364.
BaughCMStammJMRileyDO, et al.Chronic traumatic encephalopathy: neurodegeneration following repetitive concussive and subconcussive brain trauma. Brain Imaging Behav2012; 6: 244–254.
20.
McKeeACCantuRCNowinskiCJ, et al.Chronic traumatic encephalopathy in athletes: progressive tauopathy after repetitive head injury. J Neuropathol Exp Neurol2009; 68: 709–735.
21.
WashingtonPMVillapolSBurnsMP. Polypathology and dementia after brain trauma: does brain injury trigger distinct neurodegenerative diseases, or should they be classified together as traumatic encephalopathy?Exp Neurol2016; 275: 381–388.
22.
RisacherSLWestJDDeardorffR, et al.Head injury is associated with tau deposition on PET in MCI and AD patients. Alzheimers Dement (Amst)2021; 13: e12230.
MendezMF. What is the relationship of traumatic brain injury to dementia?J Alzheimers Dis2017; 57: 667–681.
25.
JohnsonVEStewartWSmithDH. Traumatic brain injury and amyloid-β pathology: a link to Alzheimer's disease?Nat Rev Neurosci2010; 11: 361–370.
26.
MohamedAZCummingPNasrallahFA. Escalation of tau accumulation after a traumatic brain injury: findings from positron emission tomography. Brain Sci2022; 12: 876.
27.
MohamedAZCummingPGotzJ, et al.Tauopathy in veterans with long-term posttraumatic stress disorder and traumatic brain injury. Eur J Nucl Med Mol Imaging2019; 46: 1139–1151.
28.
MohamedAZNestorPJCummingP, et al.Traumatic brain injury fast-forwards Alzheimer's pathology: evidence from amyloid positron emission tomorgraphy imaging. J Neurol2022; 269: 873–884.
29.
AskenBMMantyhWGLa JoieR, et al.Association of remote mild traumatic brain injury with cortical amyloid burden in clinically normal older adults. Brain Imaging Behav2021; 15: 2417–2425.
30.
JamesSNNicholasJMLaneCA, et al.A population-based study of head injury, cognitive function and pathological markers. Ann Clin Transl Neurol2021; 8: 842–856.
31.
MunroCERodrigueKMChenX, et al.History of mild traumatic brain injury appears unrelated to changes in amyloid accumulation in normal aging. Alzheimers Dement2019; 15: P1536–P1537.
32.
WangMLWeiXEYuMM, et al.Self-reported traumatic brain injury and in vivo measure of AD-vulnerable cortical thickness and AD-related biomarkers in the ADNI cohort. Neurosci Lett2017; 655: 115–120.
33.
WeinerMHarveyDHayesJ, et al.Effects of traumatic brain injury and posttraumatic stress disorder on development of Alzheimer's disease in Vietnam Veterans using the Alzheimer's disease neuroimaging initiative: preliminary report. Alzheimers Dement (N Y)2017; 3: 177–188.
34.
WeinerMWHarveyDLandauSM, et al.Traumatic brain injury and post-traumatic stress disorder are not associated with Alzheimer's disease pathology measured with biomarkers. Alzheimers Dement2023; 19: 884–895.
35.
CumminsTLDoréVFeizpourA, et al.Tau, β-amyloid, and glucose metabolism following service-related traumatic brain injury in Vietnam war veterans: the Australian imaging biomarkers and lifestyle study of aging-veterans study (AIBL-VETS). J Neurotrauma2023; 40: 1086–1097.
36.
HicksAJPonsfordJLSpitzG, et al.β-amyloid and tau imaging in chronic traumatic brain injury: a cross-sectional study. Neurology2022; 99: e1131–e1141.
37.
BlennowKZetterbergH. Biomarkers for Alzheimer's disease: current status and prospects for the future. J Intern Med2018; 284: 643–663.
38.
RoherAEEshCLKokjohnTA, et al.Amyloid beta peptides in human plasma and tissues and their significance for Alzheimer's disease. Alzheimers Dement2009; 5: 18–29.
39.
De MeyerGShapiroFVandersticheleH, et al.Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people. Arch Neurol2010; 67: 949–956.
40.
MattssonNAndreassonUZetterbergH, et al.Association of plasma neurofilament light with neurodegeneration in patients with Alzheimer disease. JAMA Neurol2017; 74: 557–566.
41.
KernSSyrjanenJABlennowK, et al.Association of cerebrospinal fluid neurofilament light protein with risk of mild cognitive impairment among individuals without cognitive impairment. JAMA Neurol2019; 76: 187–193.
42.
HarariOCruchagaCKauweJS, et al.Phosphorylated tau-Aβ42 ratio as a continuous trait for biomarker discovery for early-stage Alzheimer's disease in multiplex immunoassay panels of cerebrospinal fluid. Biol Psychiatry2014; 75: 723–731.
43.
CampbellMRAshrafzadeh-KianSPetersenRC, et al.P-tau/Aβ42 and Aβ42/40 ratios in CSF are equally predictive of amyloid PET status. Alzheimers Dement (Amst)2021; 13: e12190.
44.
TaghdiriFMultaniNTaraziA, et al.Elevated cerebrospinal fluid total tau in former professional athletes with multiple concussions. Neurology2019; 92: e2717–e2726.
45.
FranzGBeerRKampflA, et al.Amyloid beta 1-42 and tau in cerebrospinal fluid after severe traumatic brain injury. Neurology2003; 60: 1457–1461.
46.
NeseliusSBrisbyHTheodorssonA, et al.CSF-biomarkers in Olympic boxing: diagnosis and effects of repetitive head trauma. PLoS One2012; 7: e33606.
47.
OstMNylénKCsajbokL, et al.Initial CSF total tau correlates with 1-year outcome in patients with traumatic brain injury. Neurology2006; 67: 1600–1604.
48.
PapaLBrophyGMWelchRD, et al.Time course and diagnostic accuracy of glial and neuronal blood biomarkers GFAP and UCH-L1 in a large cohort of trauma patients with and without mild traumatic brain injury. JAMA Neurol2016; 73: 551–560.
49.
McCreaMBroglioSPMcAllisterTW, et al.Association of blood biomarkers with acute sport-related concussion in collegiate athletes: findings from the NCAA and department of defense CARE consortium. JAMA Network Open2020; 3: e1919771–e1919771.
50.
ShahimPTegnerYMarklundN, et al.Astroglial activation and altered amyloid metabolism in human repetitive concussion. Neurology2017; 88: 1400–1407.
51.
ShahimPPolitisAvan der MerweA, et al.Neurofilament light as a biomarker in traumatic brain injury. Neurology2020; 95: e610–e622.
52.
ShahimPZetterbergHTegnerY, et al.Serum neurofilament light as a biomarker for mild traumatic brain injury in contact sports. Neurology2017; 88: 1788–1794.
53.
WeinerMWVeitchDPAisenPS, et al.2014 Update of the Alzheimer's disease neuroimaging initiative: a review of papers published since its inception. Alzheimers Dement2015; 11: e1–120.
54.
TogaAWCrawfordKL. The Alzheimer's disease neuroimaging initiative informatics core: a decade in review. Alzheimers Dement2015; 11: 832–839.
55.
KangJHKoreckaMFigurskiMJ, et al.The Alzheimer's disease neuroimaging initiative 2 biomarker core: a review of progress and plans. Alzheimers Dement2015; 11: 772–791.
56.
FranklinEEPerrinRJVincentB, et al.Brain collection, standardized neuropathologic assessment, and comorbidity in Alzheimer's disease neuroimaging initiative 2 participants. Alzheimers Dement2015; 11: 815–822.
57.
BeckettLADonohueMCWangC, et al.The Alzheimer's disease neuroimaging initiative phase 2: increasing the length, breadth, and depth of our understanding. Alzheimers Dement2015; 11: 823–831.
58.
AisenPSPetersenRCDonohueM, et al.Alzheimer's disease neuroimaging initiative 2 clinical core: progress and plans. Alzheimers Dement2015; 11: 734–739.
59.
SaykinAJShenLYaoX, et al.Genetic studies of quantitative MCI and AD phenotypes in ADNI: progress, opportunities, and plans. Alzheimers Dement2015; 11: 792–814.
60.
JagustWJLandauSMKoeppeRA, et al.The Alzheimer's disease neuroimaging initiative 2 PET core: 2015. Alzheimers Dement2015; 11: 757–771.
61.
JackCRJrBarnesJBernsteinMA, et al.Magnetic resonance imaging in Alzheimer's disease neuroimaging initiative 2. Alzheimers Dement2015; 11: 740–756.
OvodVRamseyKNMawuenyegaKG, et al.Amyloid β concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis. Alzheimers Dement2017; 13: 841–849.
64.
KuhleJBarroCAndreassonU, et al.Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and simoa. Clin Chem Lab Med2016; 54: 1655–1661.
65.
KarikariTKPascoalTAAshtonNJ, et al.Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. Lancet Neurol2020; 19: 422–433.
KniefUForstmeierW. Violating the normality assumption may be the lesser of two evils. Behav Res Methods2021; 53: 2576–2590.
68.
SchielzethHDingemanseNJNakagawaS, et al.Robustness of linear mixed-effects models to violations of distributional assumptions. Methods Ecol Evol2020; 11: 1141–1152.
69.
BuergerKEwersMPirttiläT, et al.CSF Phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease. Brain2006; 129: 3035–3041.
70.
MattssonNZetterbergHHanssonO, et al.CSF Biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA2009; 302: 385–393.
71.
LippaSMYehPHGillJ, et al.Plasma tau and amyloid are not reliably related to injury characteristics, neuropsychological performance, or white matter integrity in service members with a history of traumatic brain injury. J Neurotrauma2019; 36: 2190–2199.
72.
AloscoMLTripodisYJarnaginJ, et al.Repetitive head impact exposure and later-life plasma total tau in former national football league players. Alzheimers Dement (Amst)2017; 7: 33–40.
73.
BernickCZetterbergHShanG, et al.Longitudinal performance of plasma neurofilament light and tau in professional fighters: the professional fighters brain health study. J Neurotrauma2018; 35: 2351–2356.
74.
RubensteinRChangBYueJK, et al.Comparing plasma phospho tau, total tau, and phospho tau-total tau ratio as acute and chronic traumatic brain injury biomarkers. JAMA Neurol2017; 74: 1063–1072.
75.
ShahimPTegnerYWilsonDH, et al.Blood biomarkers for brain injury in concussed professional ice hockey players. JAMA Neurol2014; 71: 684–692.
76.
OliveraALejbmanNJerominA, et al.Peripheral total tau in military personnel who sustain traumatic brain injuries during deployment. JAMA Neurol2015; 72: 1109–1116.
77.
AskenBMTannerJAVandeVredeL, et al.Plasma P-tau181 and P-tau217 in patients with traumatic encephalopathy syndrome with and without evidence of Alzheimer disease pathology. Neurology2022; 99: e594–e604.
78.
TurkKWGeadaAAlvarezVE, et al.A comparison between tau and amyloid-β cerebrospinal fluid biomarkers in chronic traumatic encephalopathy and Alzheimer disease. Alzheimers Res Ther2022; 14: 28.
79.
UbukataSOishiNHigashiT, et al.Spatial patterns of amyloid deposition in patients with chronic focal or diffuse traumatic brain injury using (18)F-FPYBF-2 PET. Neuropsychiatr Dis Treat2020; 16: 2719–2732.
80.
MielkeMMSavicaRWisteHJ, et al.Head trauma and in vivo measures of amyloid and neurodegeneration in a population-based study. Neurology2014; 82: 70–76.
81.
SchneiderALCSelvinELiangM, et al.Association of head injury with brain amyloid deposition: the ARIC-PET study. J Neurotrauma2019; 36: 2549–2557.
82.
MountzJPressonNMinhasD, et al.Neuroimaging of tauopathy in chronic TBI. Brain Inj2017; 31: 997–998.
83.
RobertsGWGentlemanSMLynchA, et al.Beta amyloid protein deposition in the brain after severe head injury: implications for the pathogenesis of Alzheimer's disease. J Neurol Neurosurg Psychiatry1994; 57: 419–425.
84.
RobertsGWGentlemanSMLynchA, et al.beta A4 amyloid protein deposition in brain after head trauma. Lancet1991; 338: 1422–1423.
85.
DeKoskySTAbrahamsonEECiallellaJR, et al.Association of increased cortical soluble abeta42 levels with diffuse plaques after severe brain injury in humans. Arch Neurol2007; 64: 541–544.
86.
MarklundNVedungFLubberinkM, et al.Tau aggregation and increased neuroinflammation in athletes after sports-related concussions and in traumatic brain injury patients - A PET/MR study. Neuroimage Clin2021; 30: 102665.
87.
ButlerTChiangGCNiogiSN, et al.Tau PET following acute TBI: off-target binding to blood products, tauopathy, or both?Front Neuroimaging2022; 1: 958558.
88.
SeshadriSWolfPABeiserA, et al.Lifetime risk of dementia and Alzheimer's disease. The impact of mortality on risk estimates in the Framingham Study. Neurology1997; 49: 1498–1504.
89.
PodcasyJLEppersonCN. Considering sex and gender in Alzheimer disease and other dementias. Dialogues Clin Neurosci2016; 18: 437–446.
90.
FerrettiMTIulitaMFCavedoE, et al.Sex differences in Alzheimer disease — the gateway to precision medicine. Nat Rev Neurol2018; 14: 457–469.
91.
SharpESGatzM. Relationship between education and dementia: an updated systematic review. Alzheimer Dis Assoc Disord2011; 25: 289–304.
92.
O'BryantSEJohnsonLABarberRC, et al.The health & aging brain among Latino Elders (HABLE) study methods and participant characteristics. Alzheimers Dement (Amst)2021; 13: e12202.
93.
O'BryantSEZhangFPetersenM, et al.A blood screening tool for detecting mild cognitive impairment and Alzheimer's disease among community-dwelling Mexican Americans and non-hispanic whites: a method for increasing representation of diverse populations in clinical research. Alzheimers Dement2022; 18: 77–87.
94.
O'BryantSPetersenMHallJ, et al.Characterizing plasma NfL in a community-dwelling multi-ethnic cohort: results from the HABLE study. Alzheimers Dement2022; 18: 240–250.
95.
O'BryantSEZhangFPetersenM, et al.Neurodegeneration from the AT(N) framework is different among Mexican Americans compared to non-hispanic whites: a health & aging brain among latino elders (HABLE) study. Alzheimers Dement (Amst)2022; 14: e12267.
96.
O'BryantSEPetersenMHallJR, et al.Plasma biomarkers of Alzheimer's disease are associated with physical functioning outcomes among cognitively normal adults in the multiethnic HABS-HD cohort. J Gerontol A Biol Sci Med Sci2023; 78: 9–15.
97.
HierDBObafemi-AjayiTThimganMS, et al.Blood biomarkers for mild traumatic brain injury: a selective review of unresolved issues. Biomark Res2021; 9: 70.
98.
MettingZWilczakNRodigerLA, et al.GFAP And S100B in the acute phase of mild traumatic brain injury. Neurology2012; 78: 1428–1433.
99.
PapaL. Potential blood-based biomarkers for concussion. Sports Med Arthrosc Rev2016; 24: 108–115.
100.
DaughertyJDePadillaLSarmientoK, et al.Self-reported lifetime concussion among adults: comparison of 3 different survey questions. J Head Trauma Rehabil2020; 35: E136–E143.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
